The mainstay of hemophilia treatment is impeded by a stubborn problem that can sometimes drastically reduce its efficacy.
Research shows thrombin generation assays can monitor the efficacy of hemophilia A treatment in a way that the mere monitoring of plasma FVIII activity cannot.
What is acquired hemophilia A, and why is it underdiagnosed and undermanaged? We attempt to answer these questions and more.
We discuss the importance of pain management in hemophilia care and the effort of Italian doctors to arrive at a consensus on this issue.
We compare hemophilia treatment strategies and approaches among different countries, particularly Japan and China.
We explore how the treatment landscape of hemophilia is changing as scientists race to find a permanent cure.
An increasing number of studies support the use of gene therapy in patients with hemophilia. However, several factors restrict its wide application.
We examine the relatively new prophylactic hemophilia A drug, efmoroctocog alfa, and how discuss the data on how well it works.
The clinical management of acquired hemophilia A still puzzles physicians and hematologists globally, and early diagnosis is difficult.
We explore where we are today with regards to the mortality rates of patients with hemophilia A, as well as the impact of emicizumab.